Display options
Cite
Regazzi MB, Russo D, Iacona I, et al. Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. Clin Drug Investig. 1998;16(1):25-33doi: 10.2165/00044011-199816010-00004.
Regazzi, M. B., Russo, D., Iacona, I., Sacchi, S., Visani, G., Lazzarino, M., Avvisati, G., Pelicci, P. G., Dastoli, G., Grandi, C., Spreafico, S., Grattoni, R., Galieni, P., Rupoli, S., Maiolo, A. M., Guerra, E., & Liberati, A. M. (1998). Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. Clinical drug investigation, 16(1), 25-33. https://doi.org/10.2165/00044011-199816010-00004
Regazzi, M B, et al. "Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off." Clinical drug investigation vol. 16,1 (1998): 25-33. doi: https://doi.org/10.2165/00044011-199816010-00004
Regazzi MB, Russo D, Iacona I, Sacchi S, Visani G, Lazzarino M, Avvisati G, Pelicci PG, Dastoli G, Grandi C, Spreafico S, Grattoni R, Galieni P, Rupoli S, Maiolo AM, Guerra E, Liberati AM. Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. Clin Drug Investig. 1998;16(1):25-33. doi: 10.2165/00044011-199816010-00004. PMID: 18370515.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 1998;16(1):25-33. doi: 10.2165/00044011-199816010-00004.

Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.

Clinical drug investigation

M B Regazzi, D Russo, I Iacona, S Sacchi, G Visani, M Lazzarino, G Avvisati, P G Pelicci, G Dastoli, C Grandi, S Spreafico, R Grattoni, P Galieni, S Rupoli, A M Maiolo, E Guerra, A M Liberati

Affiliations

  1. Gruppo Ematologico Retinoidi (GER), Milano, Italy.

PMID: 18370515 DOI: 10.2165/00044011-199816010-00004

Abstract

OBJECTIVE: This study investigated the pharmacokinetics of tretinoin during alternating cycles of 1 week of tretinoin treatment and 1 week drug-free in patients with Ph1+ chronic myelogenous leukaemia (CML) in the chronic phase.

PATIENTS: Eighteen patients with CML were treated with tretinoin 80 mg/m(2)/day (in two divided doses) for 7 consecutive days every other week (one cycle = 1 week on/1 week off).

RESULTS: Body systemic exposure to tretinoin as determined by the area under the plasma concentration-time curve (AUC) decreased significantly during the first week of drug administration, from (mean +/- SD) 678.3 +/- 498.1 to 258.7 +/- 272.4 microg/L.h. In about 40% of the patients the decline in plasma concentrations was >/=80%, while 17% of the population did not experience any decline. On day 7 of cycle 1, the mean apparent oral clearance (CL/F) was 2.6 times the corresponding value on day 1. After 1 week without tretinoin, the mean AUC on day 1 of cycle 2 was lower (down 15%) but not statistically different from the corresponding value observed on day 1 of cycle 1; 62% of patients showed an increase in the AUC, which was 40% higher than the corresponding value on day 7 of cycle 1. On day 1 of cycle 6, the AUC and CL/F of tretinoin during a dosage interval were not statistically different from those observed on day 1 of cycle 1 and cycle 2. On all occasions the peak plasma concentration (C(max)) was strongly correlated to the corresponding AUC. No significant change in the time to observed C(max) (t(max)) and in the elimination half-life (t((1/2))) was observed during the whole study. These results confirmed that the metabolism of tretinoin is rapidly up-regulated in CML patients, with significant declines in plasma drug exposure during the first week of drug administration. After tretinoin was discontinued, a return to the noninduced state followed a mean time-cycle similar to the induction. The strong decrease in the apparent oral drug clearance and the absence of significant variations in the drug half-life demonstrated that the presystemic extraction of tretinoin is the main cause of the marked decline in plasma drug exposure.

CONCLUSION: The favourable pharmacokinetic profile of tretinoin obtained by an intermittent regimen, 1 week on/1 week off therapy (vs continuous administration), suggests that such a therapeutic schedule is the most appropriate for the assessment of clinical efficacy in those pathologies in which its use is suitable.

References

  1. J Natl Cancer Inst. 1993 Jun 16;85(12):993-6 - PubMed
  2. J Clin Oncol. 1995 May;13(5):1238-41 - PubMed
  3. Am J Clin Nutr. 1989 Aug;50(2):370-4 - PubMed
  4. Clin Pharmacokinet. 1997 May;32(5):382-402 - PubMed
  5. Blood. 1993 Oct 1;82(7):1949-53 - PubMed
  6. N Engl J Med. 1991 May 16;324(20):1385-93 - PubMed
  7. J Clin Oncol. 1995 Oct;13(10):2517-23 - PubMed
  8. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8 - PubMed
  9. Leukemia. 1994 Jun;8(6):914-7 - PubMed
  10. Cancer Res. 1992 Jun 15;52(12):3329-34 - PubMed
  11. Leukemia. 1994 Nov;8(11):1813-6 - PubMed
  12. J Biol Chem. 1994 Apr 8;269(14):10538-44 - PubMed
  13. Leukemia. 1994 Nov;8(11):1807-12 - PubMed
  14. Ann Intern Med. 1994 Feb 15;120(4):278-86 - PubMed
  15. Blood. 1996 Jan 15;87(2):725-33 - PubMed
  16. Annu Rev Nutr. 1992;12:161-81 - PubMed
  17. J Biol Chem. 1979 Jul 25;254(14):6296-302 - PubMed
  18. Haematologica. 1997 Jan-Feb;82(1):106-21 - PubMed
  19. Drugs. 1995 Nov;50(5):897-923 - PubMed
  20. Cancer Chemother Pharmacol. 1997;39(4):349-56 - PubMed
  21. J Clin Oncol. 1995 Jun;13(6):1501-8 - PubMed
  22. Cancer. 1997 Apr 15;79(8):1574-80 - PubMed
  23. Semin Hematol. 1994 Oct;31(4 Suppl 5):14-7 - PubMed
  24. Leuk Res. 1994 Aug;18(8):587-96 - PubMed
  25. AIDS. 1996 Aug;10(9):1049-50 - PubMed
  26. Cancer Res. 1993 Feb 1;53(3):472-6 - PubMed
  27. Blood. 1992 Jan 15;79(2):299-303 - PubMed
  28. Cancer Chemother Pharmacol. 1997;40(4):335-41 - PubMed
  29. Drug Metab Dispos. 1995 Feb;23(2):227-31 - PubMed
  30. Blood. 1993 Oct 1;82(7):2175-81 - PubMed
  31. J Biol Chem. 1985 Sep 5;260(19):10590-6 - PubMed

Publication Types